The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
暂无分享,去创建一个
S. Matsumoto | K. Yoh | K. Goto | G. Ishii | K. Tsuta | M. Kodani | K. Kunimasa | Tomohiro Kato | K. Nishi | T. Nakagawa | Y. Hayashi | S. Sugawara | N. Motoi | J. Sakakibara-Konishi